儿童癫痫患者托吡酯治疗相关的肾结石与肾钙质沉着症
研究纳入40例开始托吡酯治疗的癫痫患儿,平均随访36个月,监测血电解质、尿钙/肌酐比值及肾脏超声。结果显示长期托吡酯治疗与持续性高钙尿症和代谢性酸中毒相关,4例出现肾结石和/或肾钙质沉着症,停药后缓解。基线高钙尿症患儿尿钙/肌酐比值升高更显著,且与托吡酯剂量增加相关。
要点
- 长期托吡酯治疗可致儿童持续性高钙尿症和代谢性酸中毒。
- 4例患儿出现肾结石和/或肾钙质沉着症,停药后缓解。
- 基线高钙尿症患儿尿钙升高更显著,且与剂量增加相关。
核心结论
- 儿童长期托吡酯治疗与持续性高钙尿症和代谢性酸中毒相关,可导致肾钙质沉着症和/或肾结石。
研究设计与样本
- 研究纳入40例1997年1月至2003年2月间因癫痫开始托吡酯治疗的连续患儿,平均随访36个月。
- 在托吡酯治疗前及之后每6个月检测血电解质、尿钙/肌酐比值和肾脏超声。
主要发现
- 4例患儿出现肾结石和/或肾钙质沉着症,停药后缓解。
- 40例患儿平均尿钙/肌酐比值随时间升高(P < 0.001),平均血清碳酸氢盐随时间降低(P < 0.01)。
- 尿钙排泄增加与托吡酯剂量增加相关(P = 0.039)。
关键数值与推荐
- 基线高钙尿症定义为尿钙/肌酐比值 >0.21。
- 所有开始托吡酯治疗的儿童应进行基线和随访尿钙/肌酐、血电解质检测,若尿钙/肌酐比值升至高于年龄正常水平,应定期行肾脏超声。
临床怎么用
- 对开始托吡酯治疗的癫痫患儿,应监测基线及随访尿钙/肌酐比值和血电解质。
- 若尿钙/肌酐比值升高超过年龄正常水平,应定期行肾脏超声筛查肾钙质沉着症和肾结石。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adults treated with topiramate may develop nephrolithiasis, but its frequency in children on topiramate is unknown. Topiramate inhibits renal carbonic anhydrase, which can lead to renal tubular acidosis and hypercalciuria. We studied 40 consecutive children who initiated topiramate therapy for seizures between January 1997 and February 2003, followed for a mean of 36 months. METHODS: Serum electrolytes, urinary calcium/creatinine ratios, and renal ultrasonography were performed before topiramate and every 6 months thereafter. RESULTS: Four children developed nephrolithiasis and/or nephrocalcinosis, which resolved on discontinuation of topiramate. In 40 patients, the mean urinary calcium/creatinine ratio increased over time (P < 0.001). The mean serum bicarbonate in 40 patients decreased over time (P < 0.01). Twenty-three children had urinary calcium/creatinine ratios before topiramate. Nine children with baseline hypercalciuria (defined as urinary calcium/creatinine >0.21) were compared with the 14 children with baseline normal urinary calcium excretion. A greater increase in urinary calcium/creatinine ratios occurred in hypercalciuric children (P < 0.001) and a greater decrease in serum bicarbonate levels occurred in the hypercalciuric children (P < 0.05) compared with children with baseline normal calcium excretion. Greater urinary calcium excretion was associated with increasing doses of topiramate (P = 0.039). CONCLUSION: Our study shows that long-term therapy with topiramate in children is associated with persistent hypercalciuria and metabolic acidosis, which can lead to nephrocalcinosis and/or nephrolithiasis. All children initiating topiramate therapy should have baseline and follow-up urinary calcium/creatinine studies, serum electrolytes, and periodic renal ultrasonography, if the urinary calcium/creatinine ratio increases to a level above normal for age.
引用
- Barnett SM, Jackson AH, Rosen BA, et al. Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy. Kidney Int Rep. 2018. PMID: 29854977. doi:10.1016/j.ekir.2018.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。